Xylem (XYL)
(Delayed Data from NYSE)
$119.46 USD
-2.32 (-1.91%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $119.45 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.46 USD
-2.32 (-1.91%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $119.45 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Xylem (XYL) Matches Q3 Earnings Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and -2.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) third-quarter 2019 results are expected to reflect benefits of strengthening end markets, exposure to emerging markets and product innovation. Cost and forex woes might have been drags.
Xylem (XYL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEX's Diversified Business and Buyouts Aid Despite Forex Woes
by Zacks Equity Research
IDEX (IEX) gains from a diversified business structure, solid product offerings, acquired assets and shareholder-friendly policies. Geopolitical uncertainties and forex woes are headwinds.
Forget Xylem, Invest in These 4 Industrial Stocks Instead
by Zacks Equity Research
Global uncertainties and tariffs weigh on the Industrial Products sector while technological advancements and e-retailing are positives for the space. We present four stocks that are investment worthy.
Xylem (XYL) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xylem-Planet Water to Extend Tie Up to Solve Water Issues
by Zacks Equity Research
Xylem's (XYL) partnership with Planet Water Foundation will cater to the growing requirements of clean and safe drinking water in disadvantaged communities across remote and rural areas.
The Zacks Analyst Blog Highlights: U.S. Bancorp, Duke Energy, Glaxo, Ross Stores and Xylem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: U.S. Bancorp, Duke Energy, Glaxo, Ross Stores and Xylem
Here's Why it is Worth Holding on to Xylem (XYL) Stock for Now
by Zacks Equity Research
Xylem (XYL) is likely to gain from solid growth prospects in utilities and commercial end markets, shareholder-friendly policies, and long-term tailwinds. Weakness in the European business is dragging.
Top Analyst Reports for U.S. Bancorp, Duke Energy & Glaxo
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including U.S. Bancorp (USB), Duke Energy (DUK) and Glaxo (GSK).
Xylem (XYL) Posts In-Line Earnings & Sales in Q2, Lowers View
by Zacks Equity Research
Xylem's (XYL) second-quarter 2019 earnings meet estimates and improve year over year on sales growth and margin improvement. The company lowers 2019 earnings projection.
Xylem (XYL) Q2 Earnings Meet Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and 0.02%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can High Costs & Forex Woes Hurt Xylem (XYL) in Q2 Earnings?
by Zacks Equity Research
Xylem's (XYL) second-quarter 2019 profitability will likely suffer from adverse impacts of forex woes, and high costs related to realignment initiatives, tariffs and growth investments.
Xylem (XYL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xylem (XYL) Down 6.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xylem (XYL) Gains From Solid End Markets Despite Forex Woes
by Zacks Equity Research
Xylem's (XYL) strengthening end markets, shareholder-friendly policies and healthy segmental prospects are boons. High debts and forex woes remain concerns.
Xylem (XYL) Lags Q1 Earnings & Sales Estimates, Lowers View
by Zacks Equity Research
Xylem (XYL) first-quarter 2019 earnings lag estimates and improve year over year on sales growth. It lowers 2019 earnings projection on account of first-quarter results and forex woes.
Xylem (XYL) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of -10.34% and -0.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
In first-quarter 2019, Xylem (XYL) is likely to gain from strengthening end markets, solid product portfolio, solid pricing and productivity initiatives. High costs and forex woes remain concerns.
Xylem (XYL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xylem (XYL) Q4 Earnings Meet Estimates, Rise on Solid Sales
by Zacks Equity Research
Xylem (XYL) fourth-quarter 2018 earnings meet estimates and improve year over year on sales growth and margin expansion. The company also hikes the dividend rate.
Xylem (XYL) Meets Q4 Earnings Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and 1.72%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) fourth-quarter 2018 earnings face risks arising from unfavorable foreign currency movements, tariffs and inflationary pressures. Emerging market growth and pricing actions might work in favor.
Xylem (XYL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Avoid Betting on Xylem (XYL) Stock Now
by Zacks Equity Research
Xylem (XYL) might suffer from rising cost of sales (due to implementation of tariffs), high operating expenses, unfavorable movements in foreign currencies and high debts.